Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Intrauterine Drug Delivery Systems

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Increase in Sialylated EGFR Levels by Arsenite Enhances EGF-Dependent EGFR Phosphorylation.

Journal of applied toxicology : JAT·2026

Same author

Simple formulations with only excipients for stable lyophilization and ambient-temperature storage of adeno-associated viral vectors.

International journal of pharmaceutics·2026

Same author

Enarodustat suppresses thymic stromal lymphopoietin expression via hypoxia-inducible factor-mediated c-Jun N-terminal kinases dephosphorylation.

PloS one·2026

Same author

Optimized Molecular Weight of Hydroxypropyl Cellulose in Inhaled Spray-Freeze-Dried Powders for High Deagglomeration and Pulmonary Retention Abilities.

Chemical & pharmaceutical bulletin·2026

Same author

Improved transfection methods for observation of cytoskeletal structures in primary cultured astrocytes.

Journal of cell science·2025

Same author

Public Health Center Strategies to Develop Infection Control Practices for Hospital Sinks in Kawaguchi City.

Cureus·2025

Search research articles

Related Experiment Video

Updated: May 10, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

[Sustained-release progesterone vaginal suppositories 3-development and clinical feasibility testing].

Ayako Nakayama¹, Naho Yamaguchi, Yukiko Ohno

¹Department of Pharmacy, Hoshigaoka Maternity Hospital, 27 Inoue-cho, Chikusa-ku, Nagoya 464-0026, Japan. hoshiya@toukeikai.com

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan

|June 4, 2013

Summary

New sustained-release vaginal suppositories for progesterone offer effective infertility treatment with once-daily dosing. This innovation improves upon conventional suppositories requiring multiple daily administrations.

More Related Videos

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

Related Experiment Videos

Last Updated: May 10, 2026

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

Area of Science:

Reproductive Medicine
Pharmaceutics
Drug Delivery Systems

Background:

Conventional hospital-formulated progesterone vaginal suppositories have a short half-life, necessitating frequent dosing for infertility treatment.
This limits patient compliance and therapeutic efficacy.

Purpose of the Study:

To develop and characterize sustained-release vaginal suppositories for progesterone.
To achieve effective blood progesterone concentrations with once-daily administration for infertility management.

Main Methods:

Prepared seven types of sustained-release progesterone vaginal suppositories.
Evaluated candidate suppositories based on recovery rate, reproducibility, hardness, and drug release performance.
Utilized a VOSCO S-55 and progesterone shell with embedded sustained-release progesterone tablets.
Administered the selected suppository to healthy volunteers and analyzed blood progesterone concentrations.

Main Results:

The selected sustained-release suppository demonstrated limited weight and content distribution variability.
Progesterone release rate was significantly slower compared to conventional suppositories.
Single-dose administration in volunteers extended blood progesterone concentration significantly.
Multiple administrations confirmed a sustained rise in baseline progesterone levels.
Simulations indicated once-daily dosing of the new suppository is superior to twice-daily conventional dosing.

Conclusions:

The developed sustained-release vaginal suppository effectively maintains therapeutic progesterone levels with once-daily administration.
This formulation shows significant potential for improved clinical use in infertility treatment.
The sustained-release technology offers a more convenient and effective alternative to existing progesterone vaginal suppositories.